Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes

European Commission · Grant call

UpcomingLast verified 7 Nov 2026

Part of Horizon Europe (HORIZON)

Key facts

Eligible countries: any EU member state
Provider based in: European Union
Timing: Opens 10 Feb 2027 · Deadline 16 Sep 2027
How to apply: Application portal · Apply on their site
Source: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-03

Evidence

Short excerpts from the sources, in their original language, that back the facts above.

Apply link · from the provider's datahttps://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-03
Deadline · from the provider's datahttps://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-03
Kind · from the provider's datahttps://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-03
Opens · from the provider's datahttps://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-03
Status · from the provider's datahttps://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-03

Status history

7 Nov 2026: Upcoming (first extraction)

Something wrong or out of date? Report an error.